Introduction
============

Colorectal cancer is one of the leading causes responsible for millions of death each year all over the world[@B1],[@B2]. Advance techniques has been implemented though no considerable results are observed, and metastatic diseases still suffers from poor prognosis[@B3],[@B4]. Early detection of tumor progression and metastases remains the most effective way to improve the outcomes of patients.

Conventionally, carcinoembryonic antigen (CEA) and carbohydrate antigen-19-9 (CA 19-9) etc are clinically used as routine tumor markers to monitor disease progression. Nevertheless, these markers figure-out inadequate information due to their low sensitivity[@B5]-[@B11]. Thus new concepts are emerging in search of non-invasive biological markers that could be used to evaluate the risk of disease progression. In recent years, plasma cell-free DNA (cfDNA) has led an interest as a screening tool and is regarded as potential biomarkers for tumor burden in patients with many various cancers including CRC[@B12]-[@B20]. The cfDNA has been implicated as strong diagnostic and prognostic markers because the expression of cfDNA is usually altered in malignancies[@B12]-[@B15]. It is believed that the sources of cfDNA in blood stream are necrotic and apoptotic cells[@B21]-[@B25]. However, there are several differences regarding cfDNA of diverse origins. The cfDNA released from necrotic tumor cells differs in size, whereas cfDNA fragments released from apoptotic non-tumor cells are consistent and truncated measuring 185-200 base pairs in length[@B26]-[@B29]. In affected individuals, the cfDNA is released from necrotic cells while in healthy individual cfDNA is released from apoptotic cells [@B30]-[@B31]. Integrity index has been widely accepted to deliberate the presence of cancers, which explains the ratio of longer to shorter fragments of DNAs[@B32],[@B33]. Some studies have demonstrated that integrity index is higher in patients with colorectal cancer (CRC) and other cancers [@B20]-[@B23].

Based on the features of cfDNA in biology, it has been considered and investigated quantitatively and qualitatively as a promising non-invasive diagnostic and prognostic marker since long with various results[@B34]-[@B39], however the approximated results were not distinctly marked. Two meta-analyses addressing the controversies regarding the diagnostic values of cfDNA in lung cancer[@B24] and hepatocellular Carcinoma[@B25] are recently published. But its prognostic role in cancer is still not well understood and needs to be interpreted statistically. Therefore, we performed a meta-analysis here to clarify the prognostic significance of cfDNA in blood of CRC patients, which is one of the most common malignancies worldwide.

Methods
=======

Search Strategy and study selection
-----------------------------------

Potentially relevant studies were searched via Pubmed, Embase and Science citation prior to 3-July 2015 without applying start date limit. The term of colon cancer, rectal cancer, cell-free DNA, plasma DNA, serum DNA and prognosis were searched as topics and free words at the same time (see detailed search strategy Table [S1](#SM1){ref-type="supplementary-material"}-Table [S3](#SM1){ref-type="supplementary-material"} in [supplementary material](#SM1){ref-type="supplementary-material"}). No language restrictions were imposed initially.

To yield relevant publications, we further evaluated the titles, abstract and author information of the collected studies. We contacted the authors for further studies if needed. For the analysis and full text review, only English language articles were considered. Non-research publications such as proceeding papers, editorials, comments, book chapter and other type uninvolved publications were excluded. However, cross references of relevant reviews were assessed for extra potential studies. Researchers would not appraised for detailed assessment unless the studies met the following inclusion criteria: (i) study should investigate the prognostic significance of cfDNA in colorectal cancer patients with at least one outcome (i.e., OS and RFS), (ii) the make-up of cfDNA was serum DNAs and plasma DNAs from peripheral blood (PB) rather than genomic and tumor DNAs, and (iii) studies from the same authors and institutions using the same cases were considered as duplicate publications, and only included the latest study to avoid re-assessment on the same cases.

For the meta-analysis, we endorsed the studies to be included in the final analysis through the following exclusion criteria: (i) duplicate publications, (ii) diagnostic studies, (iii) serum protein markers and genomic studies, (iv) studies with less than 20 patients, and (v) no survival or insufficient data to be statistically extracted.

Data extraction
---------------

Two reviewers (Basnet Shiva and Zhen-Yu Zhang) independently assessed the final set of articles and resolved disagreements by consensus. Data retrieved from the eligible study were: surname of the first author, number of patients, country of origin, year of publication, male/female ratio, mean/median age of patients, follow up durations, TNM staging (UICC), methods of detecting cfDNA, tumor locations, markers defining cfDNA, markers origin, sampling time, positive rate, endpoints and survival data including RFS, OS and other endpoints that could be estimated as RSF and OS.

Data processing and subgroup analysis
-------------------------------------

We used standard methods recommended for meta-analysis to statistically assess the prognostic effects of cfDNA on survival of CRC. HRs and accompanying 95%CIs were extracted individually if available. Apart from that, they were estimated using suggested methods by Parmar [@B40] and Tierney et al [@B41] based on survival data or survival curves. Besides, if HRs were mentioned by both univariate and multivariate analyses, multivariate analysis was preferable because of its consideration in possible confounding effects [@B42]

Normally, HR \>1 indicated a worse outcome. We pooled the extracted HRs with generic inverse variance method in Comprehensive Meta-analysis program (version2.2, Englewood, NJ, Biostat). Individual measures and overall effects were illustrated by forest plots [@B43]. We used Cochrane\'s Q statistics and I^2^ Statistics to test the homogeneity of the studies [@B44] and applied Random effect model only when the tests were significant (two-tailed P value≤0.1, I^2^\>50%) [@B45], [@B46].

For the studies with multiple markers, each of the markers was treated as an independent unit of analysis. If studies contained post-treatment time points, they were also meta-analyzed but also followed by sensitivity test after excluding them from the analysis. To classify the potential confounding factors related to outcomes of patients with CRC, we carried out subgroup analysis. The subgroup was stratified by tumor stages, tumor markers, methods, marker origin and size of the patients. We performed subgroup analysis only when there were two or more studies included.

Quality assessment and sensitivity analysis
-------------------------------------------

Since no standardized tools could be applicable to observational studies, we used the Newcastle-Ottawa scale (NOS) [@B47] to assess the quality of the studies because it was recommended by the Cochrane library. Sensitivity analysis was performed to test reliability of the results. The combined HRs after random removal of one included study were calculated and explored to observe the influences of a particular study on overall results. Cumulative meta-analysis was performed to test the impact of publication year on stability of final results.

Publication bias
----------------

We statistically tested for the potential presence of publication bias using funnel plots along with Begg\'s and Mazumdar rank correlation method [@B48]. All of the statistical techniques in the meta-analysis mentioned above had followed PRISMA checklist (Table [S4](#SM1){ref-type="supplementary-material"}).

Results
=======

Global characteristics
----------------------

From the extensive search made on 3^rd^ July 2015, a total no. of 1282 articles was retrieved. Among the outcomes, 1023 studies were recognized as non-English publication, duplicates and studies out of scope and another 223 articles were reported as non-research articles, all of which were excluded from detailed assessment. Notably, three out of four studies from Spindler et al [@B49]-[@B51] and one out of two studies from Philipp et al [@B52] were excluded because of significant overlapping (the same author, same institutions, time period and part data were repeated), and only most recent studies (latest submission) were given priority. After the independent full review of the rest 36 studies, nine publications [@B53]-[@B61] dealing with quantitative and qualitative analysis of cfDNA with the prognostic purpose of CRC were considered as eligible studies (Figure [1](#F1){ref-type="fig"}). The 9 studies included a total of 1022 colorectal patients published between the year 2003 and 2014, eight from Europe [@B53]-[@B59], [@B61] and one from China [@B60]. The mean patient no. per study was 114. The samples were collected before treatment (n=8) [@B53], [@B55]-[@B61] and after treatment (n=1) [@B54] One study reported cancer-related survival [@B57] which could be regarded as a subset of OS. Molecular techniques like PCR followed by sequencing [@B53], [@B54], Spectrophotometry [@B41], quantitative PCR (q-PCR) [@B42], [@B46] mutant-enriched PCR (ME-PCR) [@B57] and real-time PCR (rt-PCR) [@B58],[@B59],[@B61] were used to detect cfDNA from PB samples. Quality assessment was performed by NOS scale (Table [S5](#SM1){ref-type="supplementary-material"}) and all of the studies scored as high quality with 5 points or more. In total, all main characteristics of the eligible studies (19 units of analysis) were summarized (Table [1](#T1){ref-type="table"} and Table [S6](#SM1){ref-type="supplementary-material"}).

Heterogeneity and overall effects
---------------------------------

There was no significant heterogeneity observed in the statistical tests among study group of RFS (I^2^=32.23%, P-value=0.1820) and OS (I^2^=29.94%, P-value=0.1530). Thus we used fixed effects model. The pooled results demonstrated that the detection of cfDNA had significant value in predicting RFS (HR \[95%CI\]=2.78\[2.08-3.72\], n=7) and OS (HR \[95%CI\]=3.03\[2.51-3.66\], n=12) in patients with CRC (Figure [2](#F2){ref-type="fig"}).

Sensitivity analysis
--------------------

To test whether the results were stable, we therefore performed sensitivity analysis. First of all, when the fixed effects model was switched to random effects model to re-compute the pooled HRs, the results showed no significant changes in overall effects for RFS (HR \[95%CI\]=2.99 \[2.00-4.47\]) and OS (HR \[95%CI\]=3.02\[2.38-3.83\]). Secondly, when the single study by Ryan (2003)[@B54] with post-treatment data from RFS group was removed from the analysis, the result remained stable (HR \[95%CI\]=2.58, \[1.90-3.50\], n=6, I^2^=17.86, P-value=0.298). The results showed similar effect after the removal of the study by Schwarzenbach (2008)[@B55] with the method of spectrophotometry from the RFS group because the result was only slightly changed (HR\[95%CI\]=2.97\[2.18-4.04\], n=6, I^2^=29.89%, P-value=0.211). Similarly, sensitivity analysis showed no significant changes when removing total cfDNA from the analysis (HR \[95%CI\]=3.34, \[2.22-5.02\], n=5, I^2^=37.26, P-value=0.173). As per the study in OS group, we excluded the study by Trevisiol (2012) [@B57] which reported cancer-related survival. The analysis did not lead any obvious changes in the total effects (HR\[95%CI\]=3.00\[2.49-3.62\], n=11, I^2^=27.14%, P-value=0.186). Likewise when total cfDNA was removed from the analysis, no obvious changes was seen in the combined results (HR \[95%CI\]=3.18, \[2.57-3.94\], n=10, I^2^=39.01, P-value=0.098). Finally, the combined effects of the analysis were stable even randomly removing one particular study from RFS and OS groups (Figure [S1](#SM1){ref-type="supplementary-material"} and Figure [S2](#SM1){ref-type="supplementary-material"}). The situations were similar with cumulative meta-analysis of both groups cumulated by the year of publication (Figure [S3](#SM1){ref-type="supplementary-material"} and Figure [S4](#SM1){ref-type="supplementary-material"}).

Subgroup Analysis
-----------------

Although no significant heterogeneity was observed in our including studies either on RFS or OS. It was reported that, tumor markers, tumor stage, marker origin, methods and population size for the presence on cfDNA acted as confounding factors which might exert considerable influences on outcomes of cancer patients[@B62]. Therefore, we performed subgroup analysis stratified according to the above mentioned factors. And the findings had confirmed the sensibility. In subgroup analysis (Table [2](#T2){ref-type="table"}) followed by patient size, the results remained stable. Particularly, the combined HRs and associated CIs of both group was \>1 with narrower CIs in large patient group. The results implied studies containing larger patient number précised a better prediction in survival effects. Similarly, when stratified by stage, we found a similar direction of pooled HRs in predicting survival of patients in both localized (UICC stage I-III) and metastatic (UICC stage IV) cancer patients. However heterogeneity became significant when pooling them together (M~0~+M~1~).The subgroup analysis stratified by methods demonstrated that the combined HRs and associated CIs of both RFS and OS seemed stable, nevertheless, qPCR technique showed reliable results with narrower CIs. Finally subgroup analysis based on type of tumor markers showed both quantitative and qualitative detection of cfDNA were predictive in RFS and OS, while contributing to considerable inter-study heterogeneity, the situation was similar with marker origin. In depth analysis showed that methylated, mutant markers and total cfDNA determination were of prognostic significance.

Publication bias
----------------

The funnel plots were symmetric. Meanwhile, results of Begg\'s and Mazumdar rank correlation were not significant for both group (RFS: two-tailed P-value=0.5480, OS: two-tailed P-value=0.4507) (Figure [3](#F3){ref-type="fig"}). Hence, there were no obvious publication biases in our included studies.

Discussion
==========

After preliminary pooling 19 subgroups from 9 studies, independently stratified by marker types, markers origin, methods, tumor stage and patient size, it was proven that the presence of cfDNA could be used to predict RFS and OS in CRC.

There are some novels findings in our meta-analysis which should be taken into consideration in future studies investigating prognostic significance of cfDNA. Briefly, there are two schemes to characterized cfDNA, i.e., quantification of total cfDNA by spectrophotometry and detection of tumor specific markers by PCR based techniques along with sequencing. We observed both strategies were effective in detection of cfDNA while the combined HRs seems to be more prominent in subgroups by detection of tumor specific markers rather than those by quantification of cfDNA. It might be the reason that PCR based techniques was more sensitive and specific than non-selective cfDNA quantification. Besides, tumor specific methylations and mutations were also associated with RFS and OS of CRC, although the prognostic influences varied in a marker-dependent manner. For example, we could observe certain differences in overall effects of mHLTF, mHPP1 and mutant K-RAS groups. The subgroup analysis classified by tumor stage exhibited cfDNA could be applied in both localized and metastatic group of CRCs. However, heterogeneity increased in subgroup of stage I-IV indicating that there might be significant difference in prognosis of early and late stages CRCs, which should be treated separately to obtain accurate predictive information when estimating CRC patient survival. Further subgroup analysis based on patient size demonstrated that a larger patient size yielded more precise survival estimations with a narrower 95% CI of HRs. In addition, there was only one study reported post-treatment cfDNA (HR\[95%CI\]=6.36\[2.30-17.62\]), although it was significant. The use of cfDNA at post-treatment time points remained to be validated. As to the subgroups stratified by other markers, namely mhMLH1 and mutant BRAF, the combined effects of these two studies was insignificant (HR \[95%CI\]=2.55\[0.76-8.51\], I^2^=73.74, P-value=0.051). The culprit in the studies might be the incapacity of mhMLH1, which could be interpreted as a marker-dependent manner as mention above. Similarly in subgroup stratified by markers origin; namely serum, the result was insignificant (HR \[95%CI\]=3.09\[0.79-12.19\], I^2^=72.41, P-value=0.044).The level of heterogeneity might be due to the sample with different time point. Regarding method analysis, both PCR sequencing and qPCR were significant. However, qPCR showed more precise results with narrower 95%CI (HR \[95%CI\]=2.64\[1.90-3.66\], I^2^=20.97, P-value=0.282). Entirely, types of marker, markers origin, detection methods and tumor stage might contribute to substantial inter-study heterogeneity of included studies.

It should be noted that we encountered some limitations caused by the nature of meta-analysis, which made us to interpret the result with cautions. There were limited studies included in our meta-analysis because cfDNA was a novel marker and reported only recently. This might lead to bias based on limited data. However, sensitivity analysis showed that the combined HRs were stable and reliable for subsequent analysis. Included studies were homogenous, which was probably because of our strict inclusion criteria. We pre-expected there might be a certain degree of heterogeneity, and thus tried to perform subgroup analysis to explore the sources of existing heterogeneity (RFS, I^2^=32.23, P-value=0.182, OS, I^2^=29.94, P-value=0.153). We indeed found some confounding factors probably leading to inconsistencies among studies, i.e., methods, type of markers and tumor stage. Lastly, there were no publication biases illustrated by funnel plots and further demonstrated by Begg\'s and Mazumdar rank correlation tests.

Conclusion
==========

In conclusion, our meta-analysis has revealed the significant prognostic values of cfDNA for RFS and OS in patients with CRC. Further studies should compare the difference between conventional serum tumor markers and cfDNA as alternatives. More studies are expected to investigate sensitive tumor specific markers and compare multiple time points in different tumor stage group in order to prove the clinical utility of cfDNA.
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cfDNA

:   Cell-free deoxyribonucleic acid

CRC

:   Colorectal Cancer

RFS

:   Recurrence free survival

OS

:   Overall survival

HR

:   Hazard ratio

CI

:   Confident Interval

CEA

:   Carcinoembryonic antigen

CA19-9

:   Carbohydrate antigen 19-9

PB

:   peripheral blood

TNM staging

:   Tumor Nodes Metastasis staging

UICC

:   Union for International cancer control

NOS

:   Newcastle-Ottawa Scale

PCR

:   Polymerase Chain Reaction

q-PCR

:   quantitative Polymerase Chain Reaction

ME-PCR

:   Mutant Enriched Polymerase Chain Reaction

rt-PCR

:   real time Polymerase Chain Reaction.
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###### 

Major characteristics of included studies.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                  Country      Stage   Method               Markers                Marker origin   Sampling time    Positive rate   Endpoints   Hazard ratio       Multivariate/univariate analysis   Research quality   Reference No.
  ---------------------- ------------ ------- -------------------- ---------------------- --------------- ---------------- --------------- ----------- ------------------ ---------------------------------- ------------------ ---------------
  Bazan (2006)           Italy        I-III   PCR and sequencing   K-RAS/TP53             Plasma          Baseline         8/50            RFS         Data explorated    NR                                 High               \[53\]

  Ryan (2003)            Netherland   I-III   PCR and sequencing   Mut.KRAS coden-12,13   Serum           Post-Treatment   15/85           RFS         Reported in text   Multivariate                       High               \[54\]

  Schwarzenbach (2008)   Germany      IV      spectrophotometry    Total cfDNA            Serum           Baseline         26/55           RFS         Data explorated    NR                                 High               \[55\]

  Spindler (2014)        Denmark      IV      q-PCR                Mut.KRAS\              Plasma          Baseline         29/7/NR/86      RFS/OS      Reported in text   Multivariate                       High               \[56\]
                                                                   BRAF\                                                                                                                                                        
                                                                   Total cfDNA                                                                                                                                                  

  Trevisiol (2012)       Italy        I-IV    ME-PCR               Mut.KRAS coden-12      Serum           Baseline         11/86           OS^a^       Data explorated    NR                                 High               \[57\]

  Wallner (2006)         Germany      I-IV    Real-Time PCR        mHLTF/ mhMLH1/mHPP1    Serum           Baseline         31/24/13/104    OS          Reported in text   Univariate                         High               \[58\]

  Herbst (2008)          Germany      I-III   Real-Time PCR        mHLTF/mHPP1            Seru m          Baseline         13/6/106        OS          Reported in text   Multivariate                       High               \[59\]

  Lin (2014)             China        I-IV    q-PCR                Total cfDNA            Plasma          Baseline         NR/191          OS          Reported in text   Multivariate                       High               \[60\]

  Philipp (2014)         Germany      I-IV    Real-Time PCR        mHLTF/mHPP1            Serum           Baseline         41/57/259       OS          Data explorated    NR                                 High               \[61\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Subgroup analysis of RFS and OS studies.

  Variables            RFS                   OS                                                     
  -------------------- --------------------- ---- ------- ------- -------------------- ---- ------- -------
  *Overall*            2.78\[2.07-3.71\]     7    32.23   0.182   3.03\[2.51-3.65\]    12   29.94   0.153
  *Marker type*                                                                                     
  methylated           /                     /    /       /       2.94\[2.04-4.24\]    7    49.94   0.062
  mutant               3.34\[2.22-5.02\]     5    37.26   0.173   3.72\[2.33-5.93\]    3    10.14   0.329
  total cfDNA          2.29\[1.51-3.47\]     2    0.00    0.355   2.54\[1.71-3.79\]    2    0.00    0.926
  *Markers*                                                                                         
  mHLTF                /                     /    /       /       2.365\[1.67-3.36\]   3    0.00    0.745
  mHPP1                /                     /    /       /       4.62\[3.22-6.61\]    3    0.00    0.649
  mut.K-RAS            4.04\[1.57-10.35\]    3    58.06   0.092   3.40\[1.98-5.84\]    2    45.16   0.177
  total cfDNA          2.29\[1.51-3.47\]     2    0.00    0.355   2.54\[1.71-3.80\]    2    0.00    0.926
  others               5.35\[2.22-12.89\]    2    0.00    0.646   2.55\[0.76-8.51\]    2    73.74   0.051
  *Marker origin*                                                                                   
  serum                3.09\[0.79-12.19\]    2    72.41   0.044   3.09\[2.43-3.93\]    8    49.74   0.052
  plasma               2.75\[1.99-3.80\]     5    16.09   0.312   2.92\[2.15-3.96\]    4    0.00    0.638
  *Method*                                                                                          
  PCR and sequencing   7.24\[2.955-17.77\]   3    0.00    0.866   /                    /    /       /
  qPCR                 2.64\[1.90-3.66\]     3    20.97   0.282   3.01\[2.49-3.62\]    11   27.11   0.186
  others               /                     1    /       /       /                    1    /       /
  *Tumor stage*                                                                                     
  I-III                7.25\[3.00-17.77\]    3    0.00    0.866   2.65\[1.38-5.07\]    2    0.00    0.838
  IV                   2.48\[1.82-3.37\]     4    17.90   0.301   3.01\[2.14-4.22\]    3    0.00    0.457
  I-IV                 /                     /    /       /       3.05\[2.03-4.58\]    7    56.83   0.031
  *Patient size*                                                                                    
  ≤ median^a^          3.39\[1.79-6.39\]     4    48.73   0.119   2.98\[2.27-3.92\]    7    28.64   0.210
  \>median             2.64\[1.90-3.66\]     3    20.97   0.282   3.07\[2.37-3.98\]    5    44.98   0.122

^a^The median patient number in RFS and OS subgroups are 85 and 104, respectively.
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